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Abstract
Background: Antiretroviral treatment (ART) has been shown to have a beneficial effect on the weight evolution
but its effect on height remains unclear. We described patterns of height evolution and identified predictors of
catch-up growth in HIV-infected children on ART.
Methods: To describe the height evolution from birth to adulthood, we developed a nonlinear mixed effect model
using data from perinatally HIV-infected children who initiated ART from 1999 to 2013 in a prospective cohort study
in Thailand. The main covariates of interest were: sex, ART regimen (dual nucleoside reverse-transcriptase inhibitor,
non-nucleoside reverse transcriptase inhibitor (NNRTI)-, or protease inhibitor (PI)-based), baseline CD4 percentage,
HIV-RNA load and CDC HIV Classification stage and occurrence of AIDS-defining events.
Results: A total 477 children (43% boys) contributed 18,596 height measurements over a median duration of 6.3
years on ART (interquartile range, 3.0 to 8.3). At ART initiation, median age was 6.2 years (1.8 to 9.6), 16% of children
were underweight (weight-for-age z-score < − 2), 49% presented stunting (height-for-age z-score < − 2), and 7%
wasting (weight-for-height z-score < − 2). The most frequent regimen at ART initiation was NNRTI-based (79%). A
model with 4 components, birth length and 3 exponential functions of age accounting for the 3 growth phases
was developed and show that the height-growth velocity was inversely associated with the age at ART initiation,
the adult height was significantly lower in those who had experienced at least one AIDS-defining event while, as
expected, the model found that adult height in females was lower than in males. Age at ART initiation, type of ART
regimen, CDC stage, CD4 percentages, and HIV-RNA load were not associated with the final height.
Conclusions: The younger the children at ART initiation, the greater the effect on height-growth velocity,
supporting the World Health Organization’s recommendation to start ART as early as possible. However, final adult
height was not linked to the age at ART initiation.
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Background
HIV infection in children has been associated with growth
delays in terms of weight (wasting and underweight) and
height (stunting) [1–9]. Antiretroviral treatments (ART)
have been shown to have a positive impact on the evolu-
tion of the anthropometric parameters [8–13], but studies
have mostly focused on the improvement of the weight-
for-age z-score (WAZ) [9, 14–18]. Results of the several
studies analyzing the effect of ART on height-for-age z-
score (HAZ), a better indicator of the general develop-
ment of children in the long term [19–23] are conflicting,
some suggesting a favourable effect [24–27] and others
not [28–32]. These discrepancies may be explained by
some methodological issues: data were sometimes col-
lected among a small numbers of children, with limited
number of height measurements and growth response ana-
lysed only up to 12months after ART initiation [28–34].
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In the present study, we used data from a relatively large
cohort of children born with HIV, followed for more than
6 years and with frequent height measurements. We were
able to develop a mathematical function that describes the
height evolution of children from birth to adulthood. This
allowed to analyse the effect of ART on the growth of chil-
dren, taking into account other factors that could influ-
ence it such as sex, clinical, virological and immunological
status at the time of treatment initiation, as well as initial
ART regimen and the occurrence of AIDS-defining events
during the follow-up.
Methods
Patients and follow-up
We used data from all HIV-infected children who started
ART within the Program for HIV Prevention and Treat-
ment (PHPT) cohort study initiated in 1999 in 40 hospi-
tals in Thailand (Clinicaltrial.gov: NCT00433030).
Children’s anthropometric parameters were measured at
enrolment and at each monthly visit during the first 2
years of follow up and every 6months thereafter. HAZ,
WAZ and weight-for-height (WHZ) were computed using
the reference growth curves for Thai children updated in
2000 [35]. CD4 percentage, HIV-RNA viral load and Cen-
ters for Disease Control and Prevention HIV classification
(CDC stage) [36, 37] were assessed at enrolment and every
6months thereafter. AIDS-defining events [36, 37] were
reported at the time of their occurrence.
Descriptive statistics at ART initiation
Continuous variables were described using median and
interquartile ranges (IQR), and categorical variables were
presented as frequencies and percentages. HAZ was cat-
egorized as <− 3 SD, − 3 to <− 2 SD, − 2 to <− 1 SD
and ≥ − 1 SD. HAZ categories at ART initiation were
compared using chi-square test for categorical variables
– sex, type of ART regimen, CDC stage, WAZ and
WHZ—, and Kruskal-Wallis test for continuous vari-
ables –age, CD4 percentage and viral load. Chi-square
test was used to assess the association between the
occurrence of AIDS-defining events (ADEs) and HAZ at
last follow-up visit.
Modelling strategy and data analysis
We developed an empirical nonlinear mixed effect model
to describe each child’s final height (HT) using Monolix
(version 4.1.4) nonlinear mixed effect modelling program
(http://lixoft.com/downloads/) [38]. Firstly, a height versus
age scatter plot was drawn. As expected, the curve was
non-linear. Thereafter, a log (Height) versus age showed
that the curve could be roughly described by 3 successive
straight segments defining 3 growth phases. A sum of 3
exponential functions was then used for describing growth
as a function of age. Parameters were estimated separately
for males and females by computing the maximum likeli-
hood estimator of the parameters without any approxima-
tion of the model (no linearization) using the stochastic
approximation expectation maximization (SAEM) algo-
rithm combined with a Markov Chain Monte Carlo
(MCMC) procedure. Several models (proportional, addi-
tive, mixed, logit) were investigated to describe the re-
sidual variability (ε). The between-subject variabilities (η
or BSVs) were assumed to be exponential. The Bayesian
information criterion (BIC) was used to select the best
model. It is based on both the likelihood function and the
number of model parameters and is more conservative
than the Akaike Information Criterion.
A model including exponential functions of age corre-
sponding to 3 phases (a, b and c) was used to fit the
observations (Eq. 1):
HT ¼ HTbirth þ HTmax  HTbirthð Þ HTaþ HTbþ HTcð Þ
ð1Þ
a) from birth to age A1
HTa ¼ fa 1 exp −0:693t=A50að Þð Þ with t ¼ age
b) from age A1 to age A2
HTb ¼ fb 1 exp −0:693t=A50bð Þð Þ with t ¼ age A1
c) above age A2
HTc ¼ fc 1 exp −0:693t=A50cð Þð Þ with t ¼ age A2
where HTbirth is the birth length; HTmax the maximum
(adult) height; fa, fb and fc the fractions of adult height
gained at each phase; A50a, A50b and A50c the time dura-
tions in each phase for which 50% of HTa, HTb or HTc
are reached; and, A1 the age bounds between phases 1
and 2, and A2 between 2 and 3. Normalizing HT by 180
cm, i.e., y =HT/180, the residual variability could be set to
a logit model, and the resulting dependent variable, i.e.,
the relative height, was bound between 0 and 1.
The covariates of interest were: sex, ART regimen (dual
nucleoside reverse transcriptase inhibitor (NRTI)-, NNRTI-
or protease inhibitor (PI)-based), CD4 percentage, HIV-
RNA load and CDC stage at ART initiation (baseline) and
the occurrence of AIDS-defining events. A covariate was fi-
nally retained if i) its effect was biologically plausible, ii) a
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reduction in BIC value was observed and iii) it produced a
reduction in the variability of the parameter, as assessed by
the associated inter-subject variability. Graphical evaluation
of the goodness-of-fit was performed using observed versus
predicted height (PRED) and weighted residuals versus time
and/or weighted residuals versus PRED. The final popula-
tion model was evaluated by the normalized prediction dis-
tribution errors (NPDE) metrics [39] and the prediction-
corrected visual predictive check (VPC) [40]. Diagnostic
graphics and distribution statistics were obtained using RfN
(link on http://wfn.sourceforge.net) via the R program.
HT versus age time-courses were simulated from their
respective final population model and compared with the
observed data to evaluate the predictive performance of
the model. The vector of parameters from 100 replicates of
the database was simulated using the final model. Each
vector parameter was drawn from a distribution with a
variance corresponding to the previously estimated BSV. A
simulated residual error was added to each simulated vari-
able. The 25th, 50th and 75th percentiles of the simulated
dependent variables at each time were then overlaid on the
observed data and a visual inspection was performed.
Results
Characteristics at ART initiation and last follow-up visit
The data from 477 children were included in this ana-
lysis. Table 1 presents their characteristics at ART initi-
ation. Two-hundred and six (43%) males. Median age
was 6.2 years (interquartile range (IQR), 1.8 to 9.6), with
65 (14%) under one year, 54% were in CDC stage B or
C. Of the 477 children, 77 (16%) were underweight
(WAZ < − 2), 235 (49%) had stunting (HAZ < − 2), and
32 (7%) experienced wasting (WHZ < − 2). Forty-one
children (9%) had started therapy with dual NRTI regi-
mens (before 2003) then switched to triple combination
when it became widely available in Thailand, 79%
Table 1 Baseline characteristics of 477 HIV-infected children
N (%) or median [IQR] All Height-for-age z-score at ART initiation p-value
<−3 SD −3 to < − 2 SD − 2 to < − 1 SD ≥ − 1 SD
All 477 116 (24%) 119 (25%) 119 (25%) 123 (26%)
Male 206 (43%) 56 (48%) 55 (46%) 43 (36%) 52 (42%) 0.25a
Age (years) 6.2 [1.8–9.6] 7.7 [5.1–10.6] 7.4 [3.9–9.9] 5.6 [1.5–9.5] 2.0 [0.8–6.5] < 0.001b
ART regimen < 0.001a
Dual NRTI-based regimen 41 (9%) 1 (1%) 5 (4%) 15 (13%) 20 (16%)
PI-based regimen 57 (12%) 5 (4%) 8 (7%) 16 (13%) 28 (23%)
NNRTI-based regimen 379 (79%) 110 (95%) 106 (89%) 88 (74%) 75 (61%)
CD4 percentage 9 [2–17] 5 [1–11] 4 [1–13] 11 [4–18] 16 [10–23] < 0.001b
HIV-RNA load (log10copies/mL) 5.17 [4.69–5.67] 5.16 [4.74–5.59] 5.20 [4.66–5.62] 5.13 [4.82–5.55] 5.22 [4.41–5.89] 0.98
b
CDC HIV classification stage < 0.001a
N 87 (18%) 12 (10%) 15 (13%) 20 (17%) 40 (33%)
A 136 (28%) 25 (22%) 32 (27%) 41 (34%) 38 (31%)
B 132 (28%) 34 (29%) 32 (27%) 38 (32%) 28 (23%)
C 17 (26%) 45 (39%) 40 (33%) 20 (17%) 17 (23%)
Weight-for-age z-score < 0.001a
< −3 SD 18 (4%) 9 (8%) 7 (6%) 1 (1%) 1 (1%)
− 3 to <−2 SD 59 (12%) 33 (28%) 12 (10%) 12 (10%) 2 (2%)
− 2 to <−1 SD 196 (41%) 66 (57%) 68 (57%) 46 (39%) 16 (13%)
≥ 1 SD 204 (43%) 8 (7%) 32 (27%) 60 (50%) 104 (84%)
Weight-for-height z-score 0.72a
< −3 SD 5 (1%) 2 (2%) 2 (2%) 1 (1%) –
– 3 to <−2 SD 27 (6%) 7 (6%) 9 (7%) 6 (5%) 5 (4%)
– 2 to <−1 SD 95 (20%) 27 (23%) 25 (21%) 22 (18%) 21 (17%)
≥ −1 SD 350 (73%) 80 (69%) 83 (70%) 90 (76%) 97 (79%)
CDC Centers for Disease Control and Prevention, IQR interquartile range, N number of children in category
a Chi-square test
b Kruskal-Wallis test
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children started on NNRTI-based regimen and 12% on
PI. Of note, stunted children were significantly older at
ART initiation, more often on NNRTI, in CDC stage B
or C, with lower CD4 percentage and more likely to be
underweight (Table 1).
Over a median duration of 6.3 years (IQR, 3.0 to 8.3)
of ART, 58 (12%) children developed at least one AIDS-
defining events (ADEs), 29 (6%) children died, 92 (19%)
were lost to follow-up, and 101 (21%) were referred to
other hospitals. At the last follow-up visit, 52 (11%) of
children presented underweight, 125 (26%) stunting, and
32 (7%) wasting. There was no association between the
occurrence of an ADE and HAZ at last visit (p = 0.31)
(Table 2). We found that HAZ at baseline was signifi-
cantly different between children who had died, were
lost to follow-up, or referred compared to those who
completed the study (see Additional file 2: Table S3).
Forty-eight HIV-infected children (16 males and 32 fe-
males) had height measurements after 18 years. Their
median final height was 167 cm for boys, around the
28th percentile of the Thai norms (median = 170), and
154 cm for girls, around the 30th percentile of the Thai
norms (median = 158). Finally, the proportion of stunted
children decreased from 49% at ART initiation to 26% at
last visit. The proportions of stunting were 25% (59/239)
in children who started ART ≤6.2 years of age and 28%
(66/238) in those who started after (p-value = 0.012).
Model
A total of 18,596 height measurements were available,
i.e. a median of 121 height measurements per child
(IQR = 105–139). The basic model (Eq. 1) described
satisfactorily the data. When a constant residual vari-
ability was used, the predicted-observed (PRED-OBS)
plots both of males and females were acceptable but
the VPC showed an over estimation of the variability.
Normalizing height by 180 cm, i.e., y = Height/180, the
residual variability could be set to a logit model, and
the resulting dependent variable, i.e., the relative
height, was bound between 0 and 1. This improved
the fit and the VPC (Fig. 1). Type of ART regimen,
CDC stage, CD4%, and HIV-RNA load at baseline
were not associated with the maximum height (see
Additional file 3: Table S4).
Effect of other variables on the model
Adding the age at ART initiation, AgeART, improved the
fit, showing an inverse association between height-
growth velocity and age at ART initiation (if AgeART is
higher, the A50a, A50b or A50c parameters decrease by
a b1, b2 or b3 fraction), i.e. the older the child at ART
initiation, the slower the growth.
The final model was
if AgeART < A1
 
b1estimated if notð Þb1 ¼ 1
if AgeART > A1andAge ARTð Þ < A2
 
b2estimated if notð Þ b2 ¼ 1
if AgeART > A2
 
b3estimated if notð Þb3 ¼ 1
The Additional file 1: Table S1 and S2 provides the
estimated values of the model parameters separately for
males and females. The parameters were accurately esti-
mated, as shown by the precision of these parameters
(small relative standard errors).
The models showed a significant association between a
final adult height (HTmax) and the occurrence of ADEs
both in males (178 versus 169 cm in those without and
with ADEs, p < 0.01) and females (165 versus 159 cm,
p < 0.01) (see Additional file 1: Table S1 and S2). Age at
ART initiation, type of ART regimen, CDC stage, CD4%,
and HIV-RNA load at baseline were not associated with
the maximum height. Using either population or individ-
ual parameters from the final model, the heights predic-
tions were very good (Fig. 2).
Discussion
Based on repeated height measurements of a large num-
ber of HIV infected children in Thailand, we developed
a new model to describe the patterns of height evolution.
The best model included three phases from birth to final
adult height. This model showed that height-growth vel-
ocity was greater in children who initiated therapy at
earlier age, independently of CD4 level and CDC HIV
Classification Stage. However, the final adult height
(HTmax) was associated with the occurrence of ADEs
but not the age at ART initiation.
In this study we show that the time to reach 50% of
each phase fractional height increased with the age at
ART initiation. This is consistent with previous studies
[8, 41–47], indicating that ART initiation at an early age
Table 2 Association between Height-for-age z scores at last visit and AIDS-defining events
AIDS-defining events All Height-for-age z-score at last follow-up visit p-value
<−3 SD -3 to < −2 SD -2 to < − 1 SD ≥ − 1 SD
No 419 (88%) 41 (82%) 63 (84%) 111 (89%) 204 (90%) 0.31a
Yes 58 (12%) 9 (18%) 12 (16%) 14 (11%) 23 (10%)
a Chi-square test
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significantly increased the height-growth velocity. Also,
the maximal height (HTmax) was related to the child’s
sex –as in the general population.
Interestingly, height-growth velocity did not differ ac-
cording to the initial ART regimen, even if it was a dual
NRTI regimen as compared to a triple combination.
Other studies did not find any difference of HAZ [8,
11] and weight-growth velocity [41, 48] according to
the type of ART regimen. Also, the immunological or
virological status at baseline had no impact on the
height-growth velocity. However, the vast majority of
children of this cohort started ART with significantly
low CD4 percentages (median 9%) and it is unclear if
this would apply to children starting ART with higher
CD4 percentages. Unfortunately, some variables that
can affect final height such as gestational age at birth,
adherence, nutrition, exercise, puberty stage and gen-
etic factors (e.g. parental heights) [49–51], were not
available for the analysis.
A strength of our study is the large number of height
measurements per children allowing us to develop a
height-growth model that took into account the re-
peated measures in each individual. It has been shown
that the height catch-up was improved when ART was
initiated at an earlier age and in children with higher
baseline HAZ z-score [52]. Most studies described im-
provements in HAZ [53, 54], height gain or even per-
centage increase [25, 55, 56] in relation to ART. In one
study in Asian children among 273 perinatally HIV-in-
fected adolescents [median age at ART initiation, 11.4
years], 19% were stunted according to the Thai child
growth reference and half of those remained stunted
over time [57]. However, in most studies, the follow-up
duration was relatively short, and only one study in
Spain examined the height evolution after a median fol-
low up of 71 months [58].
In our study the type of initial ART regimen, NNRTI,
PI or dual NRTI-based therapy, was not associated with
the final height. In most of the studies in high-income
countries, protease inhibitor (PI)-based regimens were
used [26, 28, 41] in contrast to low and middle income
countries where NNRTI were primarily used as first-line
ART regimen [59, 60] following the World Health
Organization (WHO) recommendations [61].
The fact that the occurrence of ADEs decreased the
final height indicates that morbid episodes may slow-
down children’s growth and emphasizes the need for
close ART monitoring and adherence support.
There were some limitations in our study. Since
females generally attain their final adult height at a
younger age than males (around 15 years in females as
compared to around 18 years in males). The small num-
ber of children with height measures after 18 years of
age was a limitation. Indeed, 87 females had been mea-
sured after 15 years but only 16 males after 18 years,
which impacted the precision of predictions beyond this
age. Since changes in CD4 percentage and HIV-RNA
load as well as in treatment may be related to the height
velocity or final height, it could be more accurate to de-
velop more complex models including time-dependent
Fig. 1 Height, normalized for 180 cm, as a function of age (a) male (b) female: the red curve stands for the median and the blue curves for the
25th, 75th percentiles, obtained from 100 simulations of the final model. Height measurements on the Y axis are divided by180 cm
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variables. Finally, there was one girl with endocrine dis-
order which could impact her growth. However, her
growth curve was not affected by her disorder.
Conclusions
Our results show the beneficial effect of age at ART ini-
tiation on the height-growth velocity but regardless of
age at ART initiation and initial ART regimen, children
were able to catch up in terms of final adult height. This
supports the World Health Organization guidelines for
widespread ART treatment of all HIV-infected children
as soon as they are diagnosed [61].
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Fig. 2 Relative observed versus predicted height from the population and individual models fits (a) population parameters among males (b)
individual parameters among males (c) population parameters among females and (d) individual parameters among females: Y axis value 1
stands for 180 cm
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